Richard W. Joseph

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations

Medicine, Oncology, Pharmacotherapy +13

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Medicine, Immunology, Oncology +17

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg et al. · The Lancet · 2016 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.8K citations

Pharmacy, Oncology, Pharmacotherapy +17

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

David F. McDermott, Mahrukh Huseni, Michael B. Atkins et al. · Nature Medicine · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17